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Blockade of TGF- action ameliorates renal dysfunction and Fibrosis is a pathologic process that causes tissue dys-
histologic progression in anti-GBM nephritis. function and organ failure. Transforming growth factor-
Background. We tested whether the entire soluble extracel- (TGF-) is a multifunctional regulator of cell growth
lular domain of the human transforming growth factor-
and differentiation, both in physiologic and pathologic(TGF-) type II receptor, fused to the Fc portion of human
conditions. It is also well known as a key mediator ofimmunoglobulin G (IgG1) (T-ExR) and expressed in skeletal
muscles by adenovirus-mediated gene transfer (AdT-ExR), renal fibrosis in both experimental and human kidney
can ameliorate renal dysfunction and histologic progression in a diseases [1].
rat experimental anti-glomerular basement membrane (GBM) Myofibroblasts are postmitotic fibroblast-like cells
nephritis. which are responsible for increased synthesis of intersti-Methods. Anti-GBM nephritis was induced in Wistar Kyoto
tial collagens, such as type I and III collagens [2, 3]. Inrats by an intravenous injection of anti-rat glomerular basement
pathologic conditions, TGF- is the most potent activa-membrane (GBM) sera. At day 1 (24 hours after induction),
AdT-ExR (1  109 pfu/mL) was injected into the femoral tor of myofibroblasts. It is reported that TGF- modu-
muscle in the treatment group, and an adenovirus vector– lates E-cadherin expression and induces a reversible epi-
expressing bacterial -galactosidase (AdLacZ) was injected thelial-to-mesenchymal transition in epithelial cells [4]. It
into the control group. Then, clinical and histologic changes
has also been reported that in experimental anti-glomerularwere examined for 3 weeks after the induction of anti-GBM
basement membrane (GBM) nephritis, increased TGF-nephritis.
Results. T-ExR was detected in the serum at day 7, but expression in glomeruli may induce the transition of glo-
the serum concentration of T-ExR had decreased below the merular parietal epithelial cells to myofibroblasts, and
detectable level by day 14. Although blood pressure and the thus, contribute to crescent formation [5].
degree of proteinuria were similar in both groups, the deterio-
The antiproliferative effects of TGF- have alreadyration of renal function was significantly blunted in the treat-
been demonstrated in epithelial cells, whereas its growthment group. Crescent formation and interstitial fibrosis were
stimulatory effects have been observed mainly in cellsalso ameliorated in the treatment group. These histologic im-
provements were accompanied by the decreased interstitial of mesenchymal origin, such as fibroblasts [4]. Further-
infiltration of macrophages and the decreased -smooth muscle more, TGF- increases the expression of several extra-
actin (-SMA)–positive cells in the glomeruli and the intersti- cellular matrix proteins and integrin receptors for extra-tium.
cellular matrix components and inhibits the proteolyticConclusion. This study demonstrated for the first time that
degradation of this matrix [6, 7]. Sustained overexpres-the blockade of TGF- action by AdT-ExR in the early stage
of anti-GBM nephritis ameliorates the clinical and histologic sion of TGF- due to repeated injuries is considered to
progression. In addition, this study shed light on the develop- be a major cause of glomerular matrix expansion in hu-
ment of a specific gene therapy for human crescentic glomerulo- man and experimental glomerular diseases [8].nephritis.
TGF- is produced as a latent complex that requires
extracellular activation before receptor binding. Re-
cently, Ueno et al [9] reported that the entire extracellu-Key words: soluble TGF- receptor, adenovirus vector, anti-GBM ne-
phritis, renal dysfunction, crescent formation, interstitial fibrosis. lar domain of human TGF- type II receptor, fused to
the Fc portion of human immunoglobulin G (IgG1) (T-
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neutralizing its action, and prevented experimental liver (PAS) and Masson’s trichrome reagents. An investigator
fibrosis in rats. who was blind to the treatment status examined the
Although the blockade of TGF- signaling was able histologic changes. For glomerular changes, 100 glomer-
to prevent mesangial matrix expansion in anti-Thy 1.1 uli were selected at random in cross-sections obtained
nephritis, a self-limited and reversible model of glomeru- from each rat. The ratio of the crescent-positive glomer-
lonephritis [11–14], it is still unknown whether it also uli to total glomeruli was calculated as the crescent for-
ameliorates clinical and histologic deterioration in the mation ratio. The degree of glomerular crescent forma-
progressive model of glomerulonephritis. The aim of this tion was determined semiquantitatively. The percentage
study was to investigate the effects of the blockade of of area occupied by crescents in each glomeruli was esti-
TGF- signaling by AdT-ExR on clinical and histologic mated and assigned one of the following scores: 0  no
aspects in a progressive model of glomerulonephritis in crescent, 1  0% to 25%, 2  25% to 50%, 3  50%
rats. to 75%, and 4  75% to 100% [15]. The mean score
was then calculated as the crescent score. The interstitial
fibrosis in the cortex was graded semiquantitatively onMETHODS
PAS-stained and Masson’s trichrome–stained sectionsPreparation of adenovirus vectors
using a 40 magnification. A minimum of 20 fields was
AdT-ExR and AdLacZ were prepared by in vitro assessed in each specimen. The findings of interstitial
recombination in 293 cells as previously described [9, 10]. fibrosis consisted of matrix-rich expansion of the intersti-
The titer of the adenovirus was assessed by a plaque tium, which was often accompanied by distortion and
formation assay using 293 cells and was presented in collapse of the tubules and thickening of the tubular
plaque formation units (pfu). The serum concentrations basement membranes. The following semiquantitative
of soluble T-ExR were measured by enzyme-linked grade was used: grade 0, no interstitial fibrosis; grade 1,
immunosorbent assay (ELISA) as previously described less than 25% of the interstitial space showing fibrosis;
[9, 10]. grade 2, 25% to 50% of the interstitial space showing
fibrosis; and grade 3, more than 50% of the interstitialExperimental protocol
space showing fibrosis. The mean score was then calcu-
All animal procedures were conducted after approval
lated as the interstitial fibrosis score [16].
of the protocol by the Animal Care and Ethics Commit-
tee of Kobe University Graduate School of Medicine. Immunohistochemistry
Male Wister Kyoto (WKY) rats (body weight, 215 to
Kidney tissues were snap-frozen in a bath of dry ice250 g) were purchased from Charles River Japan (Shiga,
and acetone, cut into 4 m thick sections, air-dried, andJapan). All animals were housed under standard condi-
fixed with cold acetone for 5 minutes. The sections weretions and had free access to a normal laboratory diet,
then incubated with fluorescein isothiocyanate (FITC)-including water. Anti-GBM nephritis was induced by a
conjugated goat IgG fraction to human IgG, FITC-conju-single intravenous injection of rabbit anti-GBM sera (25
gated goat F(ab)2 fragment to rat IgG, and FITC-conju-L/100 g body weight; the kind gift of Drs. Y. Suzuki
gated goat affinity–purified antibody to rabbit IgG (ICNand T. Nagamatsu, Faculty of Pharmacology, Meijo Uni-
Pharmaceuticals, Inc., Aurora, OH, USA) at room tem-versity, Japan) at day 0. At day 1 (24 hours after the
perature for 60 minutes and viewed with an Olympus BXinduction of nephritis), AdT-ExR [1  109 pfu/mL,
50F reflecting microscope (Olympus Optical Co., Tokyo,diluted in 1 mL phosphate-buffered saline (PBS)] was
Japan).injected into the femoral muscles of rats in the treatment
Paraffin-embedded kidney specimens were sectioned,group, and the same dose of adenovirus vector–expressing
deparaffinized, and incubated with mouse monoclonalbacterial -galactosidase (AdLacZ) was injected into the
antibodies against -smooth muscle actin (-SMA) (IBLsame muscle in the control group. Age-matched male
Research Products Co., Cambridge, MA, USA) andWKY rats without nephritis were used as normal rats.
against rat macrophages (ED-1) (Serotec, Oxford, UK),During the experiments, blood and urine were collected
respectively, with rabbit polyclonal antibody against ratat several time points. Blood pressure was measured
regulated upon activation of normal T cells expressedusing the tail-cuff method. Rats were sacrificed at day 7
and secreted (RANTES) (Biosource International, Ca-(control group, N  7; treatment group, N  7), at day
marillo, CA, USA), or with affinity-purified goat poly-14 (control group, N  8; treatment group, N  9), and
clonal antibody raised against rat monocyte chemotacticday 21 (control group, N  7; treatment group, N  7)
protein-1 (MCP-1) (SC-1785; Santa Cruz Biotechnology,to examine histologic changes in the kidney.
Inc., Santa Cruz, CA, USA) for 60 minutes. Specimens
Histologic evaluation were then stained by standard immunoperoxidase proce-
dures according to the manufacturer’s instructionsThe longitudinally bisected kidney was embedded in
paraffin, sectioned, and stained with periodic acid-Schiff (DAKO Japan, Tokyo, Japan).
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Immunoreactivity to -SMA in glomeruli was mainly
detected in the Bowman’s capsule and cells in crescents.
In addition, the degree of immunoreactivity of cells in
crescents correlated well with that in the Bowman’s cap-
sule. Therefore, we examined 100 randomly selected glo-
meruli for examination and graded glomerular -SMA
expression as follows: grade 0, no -SMA staining; grade
1, less than 25% of the Bowman’s capsule showing
-SMA–positive staining; grade 2, 25% to 50% of the
Bowman’s capsule showing -SMA–positive staining;
grade 3, 50% to 75% of the Bowman’s capsule showing
-SMA–positive staining; grade 4, 75% to 100% of the
Bowman’s capsule showing -SMA–positive staining;
and grade 5, all of the Bowman’s capsule showing
Fig. 1. Human immunoglobulin G (IgG) staining of diseased kidney.
-SMA–positive staining. (A ) Human IgG staining at 4 days after the induction of anti-glomerular
basement membrane (GBM) nephritis in rats treated with an adenovirusImmunoreactivity to -SMA in the interstitium was
vector–expressing bacterial -galactosidase (AdLacZ) (control group).evaluated using the same semiquantitative grading sys-
(B ) Human IgG staining at 4 days after the induction in rats treated
tem as that used for grading of interstitial fibrosis. with the entire soluble extracellular domain of the human transforming
growth factor- (TGF-) type II receptor fused to the Fc portion ofThe number of ED-1–positive cells, RANTES-posi-
the human IgG1 (AdT-ExR) (treatment group). Only the rats treatedtive cells, and MCP-1–positive cells in 100 randomly se-
with adenovirus-mediated gene transfer (AdT-ExR) showed human
lected glomeruli in each cross-section was counted. IgG mainly in the glomeruli, indicating the existence of T-ExR in the
kidney.Those cells in the interstitium were counted using a 40
magnification. A minimum of 20 fields was assessed in
each specimen.
Statistical analysisTGF-1 protein measurement
The values are expressed as mean  SEM. We usedThe renal cortex was homogenized in lysis buffer [1%
the Mann-Whitney U test to compare two-group means.Triton X-100, 0.02 mol/L Tris-HCl (pH 7.5), 0.04 mol/L
Analysis of variance (ANOVA) was used to compareethylenediaminetetraacetic acid (EDTA), 1 mmol/L
three or more group means, and pairs of means werephenylmethyl sulfonyl fluoride (PMSF)]. The protein
compared post hoc using the Bonferroni-Dunn test. Thelevels of the tissue extracts were measured and adjusted
differences were evaluated with the Stat View softwareto 1.5 mg/mL. The levels of TGF-1 were then deter-
package (Abacus Concepts, Inc., Berkeley, CA, USA).mined by an ELISA kit (R & D Systems, Minneapolis,
P  0.05 was considered to be significant.MN, USA). This activity represented active TGF-1.
The assay was repeated after activation of samples by
acidification (with 1 mol/L HCl), incubation for 10 min-
RESULTSutes, and, finally, neutralization with 1.2 mol/L NaOH/
The serum concentrations of T-ExR were 3496 0.5 mol/L HEPES. The activity obtained after activation
705 ng/mL (as human IgG1) at day 7, but less than 5 ng/mLrepresented the total activity. Latent activity was derived
at days 0, 14, and 21. Direct immunofluorescence foras total activity 	 active (preactivated).
human IgG demonstrated T-ExR in glomeruli at day 4
RNA extraction and Northern blotting (Fig. 1). These findings indicate that T-ExR was se-
creted in the circulation and reached the kidney in theTotal renal cortex RNA was extracted using STAT-60
early stage of glomerulonephritis. The treatment withaccording to the manufacturer’s instructions (Tel-Test,
AdT-ExR did not affect the binding of the heteroge-Inc., Friendswood, TX, USA). TGF-1 and glyceralde-
nous (rabbit IgG) and autologous (rat IgG) antibodieshydes-3-phosphate dehydrogenase (GAPDH) cDNA
to the GBM (Fig. 2).were kindly provided by Dr. Robert E. Hammer, Depart-
Although the systolic blood pressure (day 7, 98 ment of Biochemistry and the Howard Hughes Medical
3 mm Hg vs. 110  7 mm Hg; day 14, 121  8 mm HgInstitute, University of Texas Southwestern Medical Cen-
vs. 126  6 mm Hg; day 21, 124  6 mm Hg vs. 124 ter, Dallas, Texas, and by Dr. S. Tsuneishi, Department
6 mm Hg) and the degree of proteinuria (day 7, 437 of Pediatrics, Kobe University Graduate School of Medi-
125 mg/day vs. 457  104 mg/day; day 14, 1767  127cine, Kobe, Japan, respectively. Northern blotting was
mg/day vs. 1578  82 mg/day; day 21, 1749  144 mg/performed using the standard procedure. The signals were
day vs. 1642  53 mg/day) in both groups were similarquantitated by laser densitometer (Shimadzu CS-930,
Kyoto, Japan.). (Fig. 3 A and B), the body weight of the treatment group
Zhou et al: Blockade of TGF-b in anti-GBM nephritis 95
Fig. 3. Effects of adenovirus-mediated gene transfer (AdT-ExR) on
clinical parameters. (A ) Systolic blood pressure. (B ) Proteinuria. (C )
Body weight. (D ) Blood urea nitrogen (BUN). (E ) Serum creatinine.
Symbols are: () rats treated with an adenovirus vector–expressing
bacterial -galactosidase (AdLacZ) (control group); and () rats
treated with AdT-ExR (treatment group). (A to F) denote statistically
significant differences between control and treatment groups. (A) P 
0.028; (B) P  0.021; (C) P  0.0005; (D) P  0.018; (E) P  0.0001;
and (F) P  0.0032.
tions, including red blood cells, white blood cells, and
platelet count, as well as liver transaminases, were nor-
mal in both groups. Histologic examinations of other
organs, including the liver and muscles, did not reveal
Fig. 2. Effects of adenovirus-mediated gene transfer (AdT-ExR) on
any abnormalities in either group.the binding of heterogenous (rabbit IgG) and autologous (rat IgG)
antibodies to glomerular basement membrane (GBM). Control group After the induction of anti-GBM nephritis, the renal
(A, C, E, G, and I ); treatment group (B, D, F, H, and J ). Rabbit IgG function of rats progressively deteriorated with crescent
at 2 days after the induction of anti-GBM nephritis (A, B); rabbit IgG
formation and interstitial fibrosis. The treatment withat 4 days after the induction (C, D); rat IgG at 4 days after the induction
(E, F); rat IgG at 7 days after the induction (G, H); and rat IgG at 14 AdT-ExR significantly blunted the renal dysfunction
days after the induction (I, J). There was no difference between the [blood urea nitrogen (BUN) on day 14, 21.9 1.3 mg/dL
two groups in the binding of the heterogenous (rabbit IgG) and autolo-
vs. 30.8  1.6 mg/dL, P  0.0005; and on day 21, 29.4 gous (rat IgG) antibodies to the GBM.
2.2 mg/dL vs. 37.6  1.5 mg/dL, P  0.018; serum creati-
nine on day 14, 0.31 0.02 mg/dL vs. 0.43 0.02 mg/dL,
P  0.0001; and on day 21, 0.42  0.03 mg/dL vs. 0.61 
increased significantly compared to that of the control, 0.04 mg/dL, P  0.0032] (Fig. 3 D and E).
probably due to the better appetite of the treatment Improvement of renal dysfunction was accompanied
group (day 14, 253  3% vs. 244  3% compared to by histologic improvement. The ratios of crescent forma-
day 0, P  0.028; day 21, 267  2% vs. 248  6% tion were significantly blunted in the treatment group at
day 14 and day 21, although those at day 7 were similarcompared to day 0, P  0.021; Fig. 3C). Blood examina-
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in both groups (day 7, 25.4  4.7% vs. 30.4  5.5%, P 
 magnification, P  0.012) (Figs. 4 N and Q, and 5G);
however, at day 7 and day 21, the difference was not0.05; day 14, 60.8  5.2% vs. 90.6  1.2%, P  0.0005;
day 21, 73.9  3.5% vs. 92.1  1.6%, P  0.0021; Figs. statistically significant (day 7, 14.2  1.3 vs. 12.4  0.7
per field using a 40 magnification, P 
 0.05) (Fig. 4 M4 A to F, 5A). The crescent scores were also improved
in the treatment group at day 14 and day 21, although and P); day 21, 19.3  4.8 vs. 31.5  7.3 per field using
a 40 magnification, P
 0.05) (Fig. 5G). In the glomer-those at day 7 were similar in both groups (day 7, 0.39 
0.08 vs. 0.49  0.09, P 
 0.05; day 14, 0.98  0.14 vs. uli, ED-1–positive cells were seen mainly in the glomeru-
lar capillaries and crescents. Unexpectedly, the number1.99  0.16, P  0.0021; day 21, 1.08  0.07 vs. 1.85 
0.16, P  0.0017) (Fig. 5B). In normal rats, -SMA– of ED-1–positive cells in the glomeruli in the treatment
group increased significantly compared to that of thepositive cells were not seen in the glomeruli and intersti-
tium (not shown). In rats with anti-GBM nephritis, only control group at day 14 (42.8  4.3 vs. 17.0  1.4 per
glomerulus, P  0.012) (Figs. 4 N and Q, and 5H), al-a few mesangial cells were -SMA positive at day 7, and
there was no difference in the number of -SMA– though it was similar in both groups at day 7 and day
21 (day 7, 34.3  3.8 vs. 29.7  1.8 per glomerulus, P 
positive mesangial cells between both groups (1.0  0.4
vs. 1.3  0.5 per glomerulus, P 
 0.05). However, at 0.05) (Fig. 4 M and P); day 21, 9.5  1.0 vs. 10.5 
0.7 per glomerulus, P 
 0.05) (Fig. 5H). The tubularday 14 and day 21, -SMA–positive cells were found in
Bowman’s capsules and in crescents, as well as in the RANTES expression was significantly blunted in the
treatment group compared to the control group at dayperiglomerular and peritubular interstitium. The treat-
ment with AdT-ExR significantly reduced the ratios of 14, whereas the glomerular RANTES expression, mainly
by podocytes, was similar in both groups at day 14 (inter-glomeruli, showing -SMA–positive cells at day 14 and
day 21 (day 14, 71.7 5.8% vs. 99.1 0.6%, P 0.0004; stitium, 30.7  3.8 vs. 63.5  5.1 per field using a 40
magnification, P 0.0011; glomerulus, 6.0 0.8 vs. 4.5day 21, 88.0  3.2% vs. 98.4  1.1%, P  0.0091) (Figs.
4 G, I, J, L, and 5C), and also reduced the glomerular 0.2 per glomerulus, P 
 0.05) (Fig. 4 O and R). MCP-1
expression was also detected in tubular epithelial cells-SMA scores at day 14 and day 21 (day 14, 1.96  0.36
vs. 4.01  0.24, P  0.0021; day 21, 2.85  0.29 vs. and podocytes. The tubular MCP-1 expression was sig-
nificantly blunted in the treatment group compared to4.16  0.16, P  0.0066) (Fig. 5D). In rats with anti-
GBM nephritis, interstitial fibrosis developed at day 14 the control group at day 14 (24.0  2.3 vs. 31.3  0.6 per
field using a 40 magnification, P  0.028). In contrastand day 21, although no interstitial fibrosis was seen at
day 7 (Fig. 4 A to C). The treatment also significantly to the glomerular RANTES expression, the glomerular
MCP-1 expression significantly increased in the treat-blunted the interstitial fibrosis at day 14 and day 21
(interstitial fibrosis scores on day 14, 0.95  0.12 vs. ment group compared to the control group at day 14
(10.2  0.7 vs. 4.0  1.0 per glomerulus, P  0.020, not2.04  0.0.11, P  0.0005; and on day 21, 0.95  0.14
vs. 1.75  0.20, P  0.0059) (Figs. 4 E, F, and 5E). Al- shown).
The levels of total TGF-1 protein obtained from thethough no-SMA–positive cells were seen in the intersti-
tium in both groups at day 7, the improvement of intersti- renal cortex in both the control and treatment groups
were significantly elevated compared to those of the nor-tial fibrosis was accompanied by the reduced expression
of interstitial -SMA at day 14 and day 21 (interstitial mal rats at day 14 and day 21. However, the levels ob-
tained from the treatment group were similar to those-SMA scores on day 14, 0.73  0.14 vs. 1.48  0.12,
P  0.0045; and on day 21, 0.64  0.14 vs. 1.54  0.19, obtained from the control group throughout the experi-
mental periods (Fig. 6A). The levels of TGF-1 RNAP  0.0058) (Figs. 4 H, I, K, L, and 5F). In rats with anti-
GBM nephritis, the accumulation of ED-1–positive cells obtained from the renal cortex in both the control and
treatment groups were significantly elevated comparedwas seen in the glomeruli and the interstitium. The num-
ber of ED-1–positive cells in the interstitium were ob- to those of the normal rats throughout the experimental
periods. During the early stage of glomerulonephritis,served as significantly less in the treatment group at day
14 (17.2  2.6 vs. 47.4  10.0 per field using a 40 the levels of TGF-1 mRNA expression in the treatment

Fig. 4. Effects of adenovirus-mediated gene transfer (AdT-ExR) on histologic changes. Masson’s trichrome–stained sections. (A ) Control group,
day 7. (B ) Control group, day 14. (C ) Control group, day 21. (D ) Treatment group, day 7. (E ) Treatment group, day 14. (F ) Treatment group,
day 21. (G to L) -Smooth muscle actin (-SMA) expression. (G) Control group, day 14, glomerular lesions. (H) Control group, day 14, interstitial
lesions. (I) Treatment group, day 14. (J) Control group, day 21, glomerular lesions. (K) Control group, day 21, interstitial lesions. (L) Treatment
group, day 21. (M, N, P, and Q) ED-1 expression. (M) Control group, day 7. (N) Control group, day 14. Arrows denote the interstitial infiltration
of ED-1–positive cells. (P) Treatment group, day 7. (Q) Treatment group, day 14. (200 magnification). (O and R) RANTES expression. Arrows
denote the tubular expression of RANTES. Arrowheads denote the glomerular expression of RANTES, probably by podocytes. (O) Control
group, day 14. (R) Treatment group, day 14. (400 magnification).
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Fig. 5. Effects of adenovirus-mediated gene
transfer (AdT-ExR) on histologic parame-
ters. (A ) The rate of glomeruli showing cres-
cents. (B ) Glomerular crescent score. (C ) The
rate of glomeruli showing -smooth muscle
actin (-SMA)–positive cells. (D ) Glomerular
-SMA score. (E ) Interstitial fibrosis score.
(F ) Interstitial-SMA score. (G ) The number
of interstitial ED-1–positive cells. a to n de-
note statistically significant differences be-
tween control and treatment groups. a, P 
0.0005; b, P  0.0021; c, P  0.0021; d, P 
0.0017; e, P  0.0004; f, P  0.0091; g,
P  0.0021; h, P  0.0066; i, P  0.0005; j,
P  0.0059; k, P  0.0045; l, P  0.0058;
m, P 0.012; n, P 0.012. Data are expressed
as the mean  SE. Symbols are: () control
group; () treatment group.
group were similar to those in the control group, but was considered to be a target in the treatment for kidney
fibrosis [17]. Indeed, the blockade of TGF- signalingdecreased significantly compared to those in the control
by TGF- neutralizing antibody, recombinant chimericgroups at day 21 (Fig. 6 B and C).
TGF- type II receptor, or antisense oligonucleotides
ameliorated mesangial matrix expansion in anti-Thy 1.1
DISCUSSION nephritis, a self-limited and reversible model of glomeru-
Ueno et al [9] reported that T-ExR secreted from lonephritis [11–14]. However, these studies did not dem-
AdT-ExR–infected cells bound TGF- and blocked onstrate the effects of treatment on renal function. Thus,
TGF- signaling in vitro, and that T-ExR expressed in the present study demonstrated for the first time that
skeletal muscles could be detected in the blood and could the blockade of TGF- signaling was able to ameliorate
ameliorate rat liver fibrosis in vivo without apparent or renal dysfunction and histologic damage, including cres-
local side effects. In the present study, we also detected cent formation and interstitial fibrosis in anti-GBM ne-
T-ExR in the blood and the kidney (mainly in glomeruli), phritis, a progressive model of glomerulonephritis.
suggesting that the observed effects were due to the block- It has been reported that myofibroblasts are the domi-
ade of TGF- signaling by circulating and local T-ExR, nant cells involved in matrix formation in the kidney
which was expressed in muscles remote from the kidneys. [18, 19] and that they are also the main component in
Since the overexpression of TGF- has been reported glomerular crescents; progressive interstitial fibrosis has
thus been associated with the persistence of myofi-to lead to organ fibrosis, the blockade of TGF- signaling
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meruli and reduced the glomerular -SMA scores, sug-
gesting that the blockade of TGF- signaling inhibited
the transition of glomerular parietal epithelial cells into
myofibroblasts, thus resulting in a decrease of crescent
formation.
-SMA–positive myofibroblasts also play a pivotal
role in interstitial fibrosis. Emerging evidence suggests
that myofibroblasts can be derived from tubular epithe-
lial cells by an epithelial-to-mesenchymal transition; this
event is most probably induced by TGF- [24, 25]. Re-
cently, it was reported that this process consisted of the
following four key steps: (1) loss of epithelial cell adhe-
sion; (2) de novo -SMA expression and actin reorgani-
zation; (3) disruption of tubular basement membrane;
and (4) enhanced cell migration and invasion [25]. In
the present study, -SMA–positive myofibroblasts were
mainly seen in the peritubular interstitial space in rats
with anti-GBM nephritis. Treatment with AdT-ExR
significantly reduced -SMA–positive myofibroblasts in
the interstitium, suggesting that the blockade of TGF-
signaling inhibits the transition of tubular epithelial cells
into myofibroblasts, thus resulting in a decrease in the
severity of the observed interstitial fibrosis.
In the present study, AdT-ExR did not change the
TGF-1 mRNA expression in the renal cortex by day
14. Therefore, the observed effects at day 14 were due
not to decreased levels of TGF-1 mRNA, but to the
Fig. 6. Effects of adenovirus-mediated gene transfer (AdT-ExR) on blockade of TGF- signaling. However, the TGF-1
transforming growth factor-1 (TGF-1) protein and mRNA expres-
mRNA levels in the treatment group decreased signifi-sion of renal cortex. (A ) Total TGF-1 protein levels. (B and C) TGF-1
mRNA expression. The TGF-1 mRNA/GAPDH mRNA ratios are cantly at day 21, suggesting that the blockade of TGF-
shown. A, P  0.019 vs. normal; b, P 0.0051 vs. normal; c, P  0.0004 signaling in the early stage may affect the subsequent
vs. normal; d, P  0.015 vs. normal, P  0.0339 vs. control; e, P 
TGF-1 mRNA expression. The effects of the TGF-0.0045 vs. normal; f, P  0.009 vs. normal; g, P  0.0004 vs. normal;
h, P  0.0045 vs. normal; i, P  0.0001 vs. normal; j, P  0.0018 vs. signaling blockade on TGF- mRNA levels are contro-
normal, P  0.0074 vs. control. Data are expressed as mean  SE. versial. Neutralizing TGF- with anti–TGF- antibody
Symbols are: () control group; () treatment group; ( ) normal
in anti-Thy 1.1 nephritis resulted in no change in glomer-group (rats without induction of nephritis). The number in parentheses
denotes the number of rats examined. ular TGF-mRNA expression levels [11], whereas treat-
ment with the TGF- chimeric receptor for anti-Thy 1.1
nephritis decreased glomerular TGF- mRNA expres-
sion levels [12]. The reasons for this discrepancy are
broblasts [20]. In human IgA nephropathy, the extent not clear, although different experimental designs may
of myofibroblast persistence was a predictor of outcome account for different results. The effects of AdT-ExR
and correlated with renal progressive fibrosis [21]. Myo- on the total TGF-1 protein levels were similar to those
fibroblasts were reduced in number and ultimately disap- on the TGF-1 mRNA, although the decreased levels
peared after the withdrawal of TGF-, whereas the per- of TGF-1 protein in the treatment group at day 21 were
sistent existence of myofibroblasts was associated with not statistically significant. These findings suggest that
the expression of TGF-, which leads to progressive the observed effects at day 14 were due not to the de-
fibrosis [22]. It was also reported that TGF- is associated creased levels of TGF-1 protein, but to the blockade
with the transition of glomerular parietal epithelial cells of TGF- signaling. However, as we were unable to
to myofibroblasts [5, 23]. detect active TGF-1, probably due to its short half-life
In the present study, -SMA, a marker of smooth or the low sensitivity of the measuring system, it is still
muscle cells and myofibroblasts, was detected mainly in possible that T-ExR modulated the kinetics of the
parietal epithelial cells in the glomeruli of rats with anti- TGF-1 protein, thus changing the ratio of the active
GBM nephritis, a finding that is consistent with those form to the latent form of the TGF-1 protein.
of previous reports [5, 23]. Treatment with AdT-ExR TGF- plays a role not only in matrix metabolism,
but also in the immune system [26]. It has been reportedsignificantly ameliorated the rate of-SMA–positive glo-
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that blockade of TGF- signaling in T cells by overex- compared to the control group at day 14. In contrast
to the glomerular RANTES expression, the glomerularpression of Smad7, intracellular antagonist of TGF-/
Smad signaling, prevents the development of anti-GBM MCP-1 expression significantly increased in the treat-
ment group compared to the control group at day 14.nephritis [27]. In the present study, T-ExR was detected
in the serum at day 7, but the serum concentrations Therefore, the different MCP-1 expression in the inter-
stitium and the glomeruli may account for the discrep-had decreased to below the detectable level by day 14,
suggesting that TGF- signaling was blocked mainly in ancy with respect to macrophage infiltration in the inter-
stitium and glomeruli. In cases of Thy 1.1 nephritis, athe early stage of nephritis. It is therefore possible that
treatment with AdT-ExR prevented the induction of transient accumulation of monocytes/macrophages is ob-
served within 24 hours [35]. The increased number ofnephritis by affecting the binding of anti-GBM antibody
to GBM, which then induced the observed improvement. local macrophages is sustained for up to 7 days and
declines thereafter. At day 14, the majority of the in-However, the treatment was administered 24 hours after
the induction of glomerulonephritis, and had no effects flammatory macrophages disappear from the glomeru-
lus, probably by trafficking them to draining lymph nodeson the binding of the heterogenous and autologous anti-
bodies to GBM, blood pressure, and proteinuria through- [36]. In this model, up-regulation of glomerular TGF-
was detected at day 4 and continued at least until dayout the experiments. In addition, the treatment did not
affect the histologic severity and renal function at the 14 [37]. Interestingly, the anti-Thy 1.1 antibody, when
reinjected at day 14, did not lead to macrophage accumu-early stage (day 7). These findings suggest that the treat-
ment did not affect the development of glomerulonephri- lation [35]. The up-regulation of TGF- in this nephritis
model is thus correlated not with accumulation buttis, per se, but rather that it prevented irreversible progres-
sion, including fibrous crescent formation and subsequent rather with reduced macrophage retention in the glomer-
ulus. It is possible that similar phenomena occurred ininterstitial fibrosis.
Treatment with AdT-ExR significantly blunted the the anti-GBM nephritis model.
Major side effects were not seen in the present study.interstitial infiltration of macrophages. Anti-GBM ne-
phritis resulted in massive proteinuria. Proteinuria, per However, long-term suppression of TGF- signaling
might induce severe side effects, as TGF- null mutationse, or some protein component such as a complement
in the tubular fluid, may induce tubular injuries [28]. mice have been reported to die due to wasting syndrome
accompanied by a multifocal inflammatory cell responseThis process would then result in the disruption of the
tubular basement membrane, a step in the tubular epi- and tissue necrosis [26]. Therefore, further investigation
is required to apply this strategy clinically.thelial-to-myofibroblast transition. Interstitial macro-
phage infiltration would then be expected to occur. As
mentioned above, the tubular epithelial-to-myofibroblast
CONCLUSION
transition is induced by the over-expression of TGF-.
The present study demonstrated for the first time aTherefore, the blockade of TGF- signaling might have
blockade of TGF- signaling in the early stage of anti-prevented tubular injuries, including the disruption of
GBM nephritis in rats treated with T-ExR, expressedthe tubular basement membrane, resulting in the reduc-
in skeletal muscles by adenovirus-mediated gene trans-tion of interstitial macrophage infiltration.
fer, can ameliorate renal dysfunction and progressiveIn contrast to the decreased interstitial infiltration of
histologic damage.macrophages, the treatment with AdT-ExR increased
the glomerular infiltration of macrophages. The WKY
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